PURPOSE: To assess rate of disease progression from diagnosis to initiation of treatment for Stage I-IIIB non-small-cell lung cancer (NSCLC). METHODS AND MATERIALS: Forty patients with NSCLC underwent at least two sets of computed tomography (CT) and 18-fluorodeoxyglucose positron emission tomography (PET) scans at various time intervals before treatment. Progression was defined as development of any new lymph node involvement, site of disease, or stage change. RESULTS: Median time interval between first and second CT scans was 13.4 weeks, and between first and second PET scans was 9.0 weeks. Median initial primary maximum tumor dimension (MTD) was 3.5 cm (0.6-8.5 cm) with a median standardized uptake value (SUV) of 13.0 (1.7-38.5). The median MTD increased by a median of 1.0 cm (mean, 1.6 cm) between scans for a median relative MTD increase of 35% (mean, 59%). Nineteen patients (48%) progressed between scans. Rate of any progression was 13%, 31%, and 46% at 4, 8, and 16 weeks, respectively. Upstaging occurred in 3%, 13%, and 21% at these intervals. Distant metastasis became evident in 3%, 13%, and 13% after 4, 8, and 16 weeks, respectively. T and N stage were associated with progression, whereas histology, grade, sex, age, and maximum SUV were not. At 3 years, overall survival for Stage III patients with vs. without progression was 18% vs. 67%, p = 0.05. CONCLUSIONS: With NSCLC, treatment delay can lead to disease progression. Diagnosis, staging, and treatment initiation should be expedited. After 4-8 weeks of delay, complete restaging should be strongly considered. Copyright Â
PURPOSE: To assess rate of disease progression from diagnosis to initiation of treatment for Stage I-IIIB non-small-cell lung cancer (NSCLC). METHODS AND MATERIALS: Forty patients with NSCLC underwent at least two sets of computed tomography (CT) and 18-fluorodeoxyglucose positron emission tomography (PET) scans at various time intervals before treatment. Progression was defined as development of any new lymph node involvement, site of disease, or stage change. RESULTS: Median time interval between first and second CT scans was 13.4 weeks, and between first and second PET scans was 9.0 weeks. Median initial primary maximum tumor dimension (MTD) was 3.5 cm (0.6-8.5 cm) with a median standardized uptake value (SUV) of 13.0 (1.7-38.5). The median MTD increased by a median of 1.0 cm (mean, 1.6 cm) between scans for a median relative MTD increase of 35% (mean, 59%). Nineteen patients (48%) progressed between scans. Rate of any progression was 13%, 31%, and 46% at 4, 8, and 16 weeks, respectively. Upstaging occurred in 3%, 13%, and 21% at these intervals. Distant metastasis became evident in 3%, 13%, and 13% after 4, 8, and 16 weeks, respectively. T and N stage were associated with progression, whereas histology, grade, sex, age, and maximum SUV were not. At 3 years, overall survival for Stage III patients with vs. without progression was 18% vs. 67%, p = 0.05. CONCLUSIONS: With NSCLC, treatment delay can lead to disease progression. Diagnosis, staging, and treatment initiation should be expedited. After 4-8 weeks of delay, complete restaging should be strongly considered. Copyright Â
Authors: G Kasymjanova; D Small; V Cohen; R T Jagoe; G Batist; W Sateren; P Ernst; C Pepe; L Sakr; J Agulnik Journal: Curr Oncol Date: 2017-10-25 Impact factor: 3.677
Authors: Monica L L Mullin; Audrey Tran; Breanne Golemiec; Christopher J L Stone; Christine Noseworthy; Nicole O'Callaghan; Christopher M Parker; Geneviève C Digby Journal: JCO Oncol Pract Date: 2020-07-08
Authors: Amelia W Maiga; Stephen A Deppen; Rhonda Pinkerman; Carol Callaway-Lane; Pierre P Massion; Robert S Dittus; Eric S Lambright; Jonathan C Nesbitt; David Baker; Eric L Grogan Journal: Ann Thorac Surg Date: 2017-10-21 Impact factor: 4.330
Authors: Jingbo Wang; Pawinee Mahasittiwat; Ka Kit Wong; Leslie E Quint; Feng-Ming Spring Kong Journal: Lung Cancer Date: 2012-07-28 Impact factor: 5.705
Authors: Michelle C Salazar; Joshua E Rosen; Zuoheng Wang; Brian N Arnold; Daniel C Thomas; Roy S Herbst; Anthony W Kim; Frank C Detterbeck; Justin D Blasberg; Daniel J Boffa Journal: JAMA Oncol Date: 2017-05-01 Impact factor: 31.777
Authors: C Paul; M Carey; A Anderson; L Mackenzie; R Sanson-Fisher; R Courtney; T Clinton-McHarg Journal: Eur J Cancer Care (Engl) Date: 2011-11-23 Impact factor: 2.520